Enhancing ACT with o9R
July 27, 2022
Adoptive T cell therapy has come a long way in recent years, but it typically requires lymphodepleting pre-treatment, which can limit patient eligibility, and its efficacy is still limited in many patients. In recent efforts to improve ACT, particularly for solid tumors, Kalbasi, Siurala, and Su et al. engineered T cells with orthogonal...
Implantable microdevice provides insights on cancer drug combinations
July 20, 2022
Drugs that treat cancer are numerous and diverse, and while some patients may respond well to individual drugs, many can benefit from rational drug combinations. However, testing combinations of drugs in mice can be a long, arduous, and costly process. To more efficiently test cancer drugs in mice, Tatarova et al. developed the...
Resident memory T cells are ready to respond in neoadjuvant checkpoint blockade
July 13, 2022
Immune checkpoint blockade (ICB) has exciting potential in treating oral squamous cell cancers (OSCCs) in the neoadjuvant setting (i.e. prior to surgery). Although the identity of the responding T cells remains to be determined, tissue-resident memory (Trm) T cells, which play key roles in long-term immunity and can be rapidly engaged for effector...
Reactivating viral immunity to treat non-viral tumors
July 6, 2022
T cell function and infiltration are inhibited in the tumor microenvironment (TME), which can be challenging to overcome with therapeutic vaccination, and approaches to effective activation of T cells in situ are needed. Cytomegalovirus (CMV) causes predominantly asymptomatic infections and is highly prevalent in humans. T cell responses against CMV are long-lived, increase with...